PMID- 32332680
OWN - NLM
STAT- MEDLINE
DCOM- 20200511
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 17
DP  - 2020 Apr
TI  - Changes in inner retinal layer thickness in patients with exudative age-related 
      macular degeneration during treatment with anti-vascular endothelial growth 
      factor.
PG  - e19955
LID - 10.1097/MD.0000000000019955 [doi]
LID - e19955
AB  - The aim of this study was to identify any changes that occur in the retinal nerve 
      fiber layer (RNFL) and ganglion cell-inner plexiform layer (GC-IPL) in patients 
      with exudative age-related macular degeneration (AMD) during treatment with 
      anti-vascular endothelial growth factor (VEGF) injections.Patients were enrolled 
      in this retrospective study if they had exudative AMD, had received at least 3 
      injections of ranibizumab or aflibercept, and had a minimum of 12 months of 
      follow-up. We analyzed the changes in the RNFL and GC-IPL using spectral-domain 
      optical coherence tomography in rescan mode.Fifty-two eyes of 52 patients who had 
      been treated with repeated anti-VEGF injections for exudative AMD were included. 
      At the final visit, there was no significant between-group difference in 
      best-corrected visual acuity or intraocular pressure. There was a significant 
      decrease in central macular thickness in all groups (P < .05). There was a 
      decrease in RNFL thickness that was only statistically significant in the 
      ranibizumab group and when the ranibizumab or aflibercept groups were combined 
      (P = .036 and .044, respectively). The thickness of the GC-IPL layer was 
      significantly decreased in the aflibercept and total group (P = .035 and 
      P = .048, respectively).The thicknesses of the RNFL and GC-IPL decreased in 
      patients with exudative AMD who underwent repeated anti-VEGF injections.
FAU - Lee, Seong Woo
AU  - Lee SW
AD  - Department of Ophthalmology, Sanggye Paik Hospital, Inje University, Seoul.
FAU - Sim, Ha Eun
AU  - Sim HE
AD  - Department of Ophthalmology, Sanggye Paik Hospital, Inje University, Seoul.
FAU - Park, Jae Yong
AU  - Park JY
AD  - Department of Ophthalmology, Sanggye Paik Hospital, Inje University, Seoul.
FAU - Kim, Jae Suk
AU  - Kim JS
AD  - Department of Ophthalmology, Sanggye Paik Hospital, Inje University, Seoul.
FAU - Chang, In Beom
AU  - Chang IB
AD  - Department of Ophthalmology, Busan Paik Hospital, Inje University, Busan.
FAU - Park, Young Soon
AU  - Park YS
AD  - Eye love eye Clinic, Seoul, South Korea.
FAU - Hwang, Je Hyung
AU  - Hwang JH
AD  - Department of Ophthalmology, Sanggye Paik Hospital, Inje University, Seoul.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vascular Endothelial Growth Factors)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Macular Degeneration/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Ranibizumab/pharmacology/therapeutic use
MH  - Receptors, Vascular Endothelial Growth Factor/therapeutic use
MH  - Recombinant Fusion Proteins/pharmacology/therapeutic use
MH  - Retina/*pathology/physiopathology
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Vascular Endothelial Growth Factors/pharmacology/*therapeutic use
MH  - *Weights and Measures
PMC - PMC7220743
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/04/26 06:00
MHDA- 2020/05/12 06:00
PMCR- 2020/04/24
CRDT- 2020/04/26 06:00
PHST- 2020/04/26 06:00 [entrez]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2020/05/12 06:00 [medline]
PHST- 2020/04/24 00:00 [pmc-release]
AID - 00005792-202004240-00091 [pii]
AID - MD-D-19-08837 [pii]
AID - 10.1097/MD.0000000000019955 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(17):e19955. doi: 10.1097/MD.0000000000019955.